In Vitro Acoustic Characterization of Three Phospholipid Ultrasound Contrast Agents from 12 to 43 MHz

Abstract

The acoustic properties of two clinical (Definity, Lantheus Medical Imaging, North Billerica, MA, USA; SonoVue, Bracco S.P.A., Milan, Italy) and one pre-clinical (MicroMarker, untargeted, Bracco, Geneva, Switzerland; VisualSonics, Toronto, ON, Canada) ultrasound contrast agent were characterized using a broadband substitution technique over the ultrasound frequency range 12–43 MHz at 20 ± 1°C. At the same number concentration, the acoustic attenuation and contrast-to-tissue ratio of the three native ultrasound contrast agents are comparable at frequencies below 30 MHz, though their size distributions and encapsulated gases and shells differ. At frequencies above 30 MHz, native MicroMarker has higher attenuation values and contrast-to-tissue ratios than native Definity and SonoVue. Decantation was found to be an effective method to alter the size distribution and concentration of native clinical microbubble populations, enabling further contrast enhancement for specific pre-clinical applications.

Low‐Energy Ultrasound Treatment Improves Regional Tumor Vessel Infarction by Retargeted Tissue Factor

“…Since we could not obtain Luminity in Europe any more, we had to switch to another clinically approved lipid shell contrast agent, SonoVue, which shows similar responses to insonation pulses, as described before. 36,37 The experimental setup consisted of a focused US transducer (H-102; Sonic Concepts, Inc, Bothell, WA) with a center frequency of 1.1 MHz, an active diameter of 64.0 mm with a central opening of 20 mm, and a geometric focal length of 62.6 mm. The transducer is connected by its impedance-matching network ( Figure 1A).…”

Ultrasound‐mediated therapies for the treatment of biofilms in chronic wounds: a review of present knowledge

“…Therefore, gas diffuses from the smaller bubbles to the larger ones, leading to dissolution and disappearance of the smaller bubbles. It is well documented that factors such as shell composition, fabrication method used, the relative chemical environment and temperature can substantially influence MB size and its temporal evolution (Mulvana et al, 2010;Sun et al, 2014;Lee et al, 2015b;Taylor et al, 2017).…”

Multimodal approach to assess tumour vasculature and potential treatment effect with DCE‐US and DCE‐MRI quantification in CWR22 prostate tumour xenografts

“…The microbubbles (MicroMarker, Fujifilm VisualSonics, Toronto, Canada) used in this study have a mean diameter ranging from 2.3 to 2.9 µm , while conventional microbubbles present a mean distribution between 1 and 10 µm . The gas content of the microbubbles is exhaled via the lungs, and the shell is metabolized or filtered by the kidney and eliminated by the liver .…”